Verseon’s computational drug-discovery platform designs candidates that probably wouldn’t be found with conventional methods, according to CEO Adityo Prakash. Discover his vision of “re-routing the pharmaceutical industry” and why he believes Verseon’s approach is paving the way for next-level drug discovery. Gain insights into Verseon’s refusal to license its technology as a tool or service. Find out which other companies are exploring computational drug discovery and development, and learn about the four main approaches. Gain insights into the company’s blockchain-based subsidiary, BlockRules, which is designed to challenge traditional drug development funding models through the process of “tokenization” of securities.